Heparin chromatography as an


Journal

mAbs
ISSN: 1942-0870
Titre abrégé: MAbs
Pays: United States
ID NLM: 101479829

Informations de publication

Date de publication:
Historique:
entrez: 27 11 2019
pubmed: 27 11 2019
medline: 9 1 2021
Statut: ppublish

Résumé

The pharmacokinetic (PK) properties of therapeutic antibodies directly affect efficacy, dose and dose intervals, application route and tissue penetration. In indications where health-care providers and patients can choose between several efficacious and safe therapeutic options, convenience (determined by dosing interval or route of application), which is mainly driven by PK properties, can affect drug selection. Therapeutic antibodies can have greatly different PK even if they have identical Fc domains and show no target-mediated drug disposition. Biophysical properties like surface charge or hydrophobicity, and binding to surrogates for high abundant off-targets (e.g., baculovirus particles, Chinese hamster ovary cell membrane proteins) were proposed to be responsible for these differences. Here, we used heparin chromatography to separate a polyclonal mix of endogenous human IgGs (IVIG) into fractions that differ in their PK properties. Heparin was chosen as a surrogate for highly negatively charged glycocalyx components on endothelial cells, which are among the main contributors to nonspecific clearance. By directly correlating heparin retention time with clearance, we identified heparin chromatography as a tool to assess differences in unspecific cell-surface interaction and the likelihood for increased pinocytotic uptake and degradation. Building on these results, we combined predictors for FcRn-mediated recycling and cell-surface interaction. The combination of heparin and FcRn chromatography allow identification of antibodies with abnormal PK by mimicking the major root causes for fast, non-target-mediated, clearance of therapeutic, Fc-containing proteins.

Identifiants

pubmed: 31769731
doi: 10.1080/19420862.2019.1683432
pmc: PMC6927760
doi:

Substances chimiques

Histocompatibility Antigens Class I 0
Immunoglobulins, Intravenous 0
Receptors, Fc 0
Heparin 9005-49-6
Fc receptor, neonatal TW3XAW0RCY

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1683432

Références

MAbs. 2015;7(5):912-21
pubmed: 26018774
J Biol Chem. 2015 Feb 13;290(7):4282-90
pubmed: 25538249
Proc Natl Acad Sci U S A. 2015 May 12;112(19):5997-6002
pubmed: 25918417
Drug Discov Today. 2006 Jan;11(1-2):81-8
pubmed: 16478695
J Mol Biol. 2007 May 4;368(3):652-65
pubmed: 17362988
MAbs. 2018 Jul;10(5):803-813
pubmed: 29621428
J Biol Chem. 2010 Feb 12;285(7):4826-36
pubmed: 20018855
MAbs. 2016 Jul;8(5):969-82
pubmed: 27111637
MAbs. 2015;7(6):1084-93
pubmed: 26337808
Mol Immunol. 2013 Dec;56(4):660-74
pubmed: 23917469
PLoS One. 2013;8(2):e57479
pubmed: 23468998
AAPS J. 2012 Sep;14(3):554-8
pubmed: 22610647
MAbs. 2018 Nov-Dec;10(8):1322-1331
pubmed: 30130450
J Immunol Methods. 2012 Jan 31;375(1-2):20-9
pubmed: 21939661
MAbs. 2016 Oct;8(7):1269-1275
pubmed: 27610650
MAbs. 2016 Aug-Sep;8(6):1064-78
pubmed: 27232760
Mol Cell Proteomics. 2017 Mar;16(3):451-456
pubmed: 28062799
Annu Rev Biochem. 1999;68:729-77
pubmed: 10872465
Int J Pharm. 2013 Jan 2;440(1):83-98
pubmed: 22227342
Protein Eng Des Sel. 2013 Oct;26(10):663-70
pubmed: 24046438
Protein Eng Des Sel. 2010 May;23(5):385-92
pubmed: 20159773
Clin Transl Sci. 2019 Mar;12(2):130-139
pubmed: 30414357
MAbs. 2014 Jul-Aug;6(4):928-42
pubmed: 24802048
MAbs. 2014;6(5):1255-64
pubmed: 25517310
J Immunol. 2006 Jan 1;176(1):346-56
pubmed: 16365427
J Immunol Methods. 2018 Nov;462:101-105
pubmed: 30030147
MAbs. 2012 Nov-Dec;4(6):753-60
pubmed: 23778268
Mol Immunol. 2006 Mar;43(9):1462-73
pubmed: 16139891
J Pharmacokinet Pharmacodyn. 2016 Aug;43(4):427-46
pubmed: 27377311
MAbs. 2015;7(3):483-93
pubmed: 25695748
BioDrugs. 2014 Apr;28(2):171-80
pubmed: 24150980
Int Immunol. 2001 Dec;13(12):1551-9
pubmed: 11717196
Int Immunol. 2006 Dec;18(12):1759-69
pubmed: 17077181
PLoS Biol. 2016 Aug 19;14(8):e1002533
pubmed: 27541692
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):944-949
pubmed: 28096333
Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18601-6
pubmed: 25512516
MAbs. 2015;7(2):331-43
pubmed: 25658443
Clin Pharmacokinet. 2013 Feb;52(2):83-124
pubmed: 23299465
J Pharm Sci. 2004 Nov;93(11):2645-68
pubmed: 15389672
MAbs. 2013 Jul-Aug;5(4):576-86
pubmed: 23765230

Auteurs

Thomas E Kraft (TE)

Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.

Wolfgang F Richter (WF)

Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.

Thomas Emrich (T)

Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.

Alexander Knaupp (A)

Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.

Michaela Schuster (M)

Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.

Andreas Wolfert (A)

Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.

Hubert Kettenberger (H)

Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH